Benitec Biopharma Inc.
NASDAQ:BNTCBiotechnology
+$0.36 today
- Market cap
- $288.53M
- Beta
- 0.28
- P/E (TTM)
- -12.3
- EPS (TTM)
- -$0.99
Volume 0.13M
Average 0.11M
BNTC Total Non-current Assets
All assets not expected to be converted to cash within one year.
Benitec Biopharma Inc.NASDAQ: BNTC
Total Non-current Assets · Q3 FY2026 · quarter ended Mar 2026
Total non-current assets falls 18.0% from a year ago
Total non-current assets stood at $983K at the end of Q3 FY2026, down 18.0% from a year earlier and down 9.5% from the prior quarter. Over 3 fiscal years it compounded at -2.3% a year.
Context
- Total non-current assets amounted to 0.5% of total assets at the end of Q3 FY2026, down 0.6 pp from a year earlier.
- Total non-current assets increased in 1 of the last 3 fiscal years.
What to watch
Whether total non-current assets keeps falling in the next quarterly balance sheet after a -18.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 1.07M USD
- Year-over-year change
- +100.4%
- 4-year CAGR
- +8.6%
| Period | Period end | Total Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | 1.07M | +100.4% |
| FY2024 | 2024-06-30 | 536K | -27.1% |
| FY2023 | 2023-06-30 | 735K | -36.3% |
| FY2022 | 2022-06-30 | 1.15M | +49.5% |
| FY2021 | 2021-06-30 | 771K | — |
Total Non-current Assets vs competitors
How BNTC compares with its peers on the latest reported figures
- BNTC's Mar 2026 total non-current assets of $983K is the 9th highest of the 10 companies compared; the peer median is $53.37M.
- Its year-over-year change of -18.0% is the 9th highest of 10, against a peer median of -10.5%.
- Total non-current assets amounts to 0.5% of total assets for BNTC, versus a peer median of 32.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | $229.69M | +6.2% | -10.1% | 43.0% | |
| Mar 2026 | $158.23M | +21.2% | +33.4% | 30.0% | |
| Mar 2026 | $153.11M | +53.8% | +25.2% | 56.3% | |
| Mar 2026 | $78.38M | +166.5% | +27.9% | 36.7% | |
| Mar 2026 | $53.37M | -13.6% | -5.7% | 48.7% | |
| Mar 2026 | $26.1M | -14.4% | -12.6% | 6.2% | |
| Mar 2026 | $18.35M | -10.5% | +23.7% | 32.3% | |
| Mar 2026 | $16.39M | -13.3% | -11.8% | 6.2% | |
| Mar 2026 | $983K | -18.0% | -2.3% | 0.5% | |
| Mar 2026 | $68K | -72.0% | -49.2% | 0.4% | |
| Peer median (excluding BNTC) | $53.37M | -10.5% | -5.7% | 32.3% | |
Competitors are the stored peer set for BNTC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Benitec Biopharma Inc.
NASDAQ:BNTC
Intrinsic Alpha fair value
Locked
Current Price
$8.27
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.